Caprion

Finding proteins that hit the mark

News

CAPRION LEADS A NEW PERSONALIZED MEDICINE PARTNERSHIP FOR CANCER

Montréal, February 15, 2013 – The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).  The public-private partnership will be focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and abroad. The investment, to be disbursed over a 4 year period, will be supplemented with $11.1 million of funding from the private sector partners, for a total project value of $21.1 million.

The PMPC will be under the leadership of Caprion Proteome, a Montreal-based biotech company specializing in the discovery and development of protein-based diagnostic biomarkers.  The other partners will include the Québec Clinical Research Organization in Cancer (Q-CROC), a multidisciplinary network of clinicians, academic scientists and other members of the medical community involved in clinical and translational cancer research, as well as private partners Oncozyme Pharma, Pfizer Canada, Sanofi Canada and TELUS Health. 

As part of the projects supported through this partnership, state-of-the-art genomic, proteomic, bioinformatic and information technology platforms will be implemented to develop and deploy novel biomarkers and targeted therapeutic strategies in the healthcare system for the treatment of lung, colon and breast cancers:The sequence of our genome or the profile of the proteins in our blood can be used to accurately predict disease progression or treatment outcome. Our partnership will integrate advanced technology platforms with clinical research to accelerate the development and clinical deployment of novel personalized healthcare solutions.  Caprion has pioneered such strategies for years, and with our partners, we are committed to delivering tangible results to provide more targeted diagnosis and treatments for cancer,” said Martin LeBlanc, President and Chief Executive Officer of Caprion Proteome. 

Personalized medicine has been coined to describe the use of specific patient information gathered from tumour, blood or other specimens to characterize disease subtype and select the optimal treatment. The rapid progress in clinical research enables us to decipher the underpinnings of cancer and to develop specific diagnostic tools and targeted drugs to treat specific subtypes of common cancers such as lung, colon or breast. It is critical that these new tools and medicines be deployed for the benefit of patients across Québec,” said Gerald Batist, Professor of Oncology at McGill University and Co-director of the Q-CROC and Director of the Segal Cancer Center at the Jewish General Hospital.  “While technology has been progressing rapidly, it will be critical to prepare our healthcare system to integrate the wealth of new molecular information and educate professionals in the practice of personalized medicine,” he added.

The PMPC project stemmed from the Stratégie québécoise de la recherche et de l’innovation (SQRI) that was created by the Government of Québec to advance knowledge and accelerate the deployment of innovative personalized medicine solutions to the bedside.  The partnership, in collaboration with the Ministère de la santé et des services sociaux (MSSS), was also built to strengthen the cooperation between the private and the public research sectors including academic healthcare institutions and universities.

About the Personalized Medicine Partnership for Cancer (PMPC)

The PMPC is a not-for-profit organization that aims at positioning Québec as a global leader in personalized medicine solutions to cancer patients.  The PMPC project was selected based on the needs identified through a large consultation of 140 Québec leaders to address the challenges in the implementation of personalized healthcare in Québec.  The broad network of partners and collaborators with expertise spanning molecular biology, genomics, proteomics, clinical management, pharmacoeconomics, ethics and information technology will deliver integrated solutions to be efficiently implemented in the healthcare systemThe outcomes of the PMPC projects are expected to have a measurable impact on the clinical diagnosis and therapeutic management of various cancers as well as the efficiency and costs of the healthcare system.  For more information please visit www.pmpc-org.com.

About Caprion Proteome

Caprion Proteome is the leading provider of proteomics biomarker and immune monitoring services to the pharmaceutical and biotechnology industry.  Its proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry (MS) platform that enables a comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Its proprietary immune monitoring platform, ImmuneCarta®, offers multiplex cell flow cytometry analysis for functional analyses of innate and adaptive immune responses.  Caprion also leverages CellCarta® to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases.  With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has a decade of experience providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients. Caprion acquired PPD Biomarker Discovery Sciences, LLC from PPD Inc. in 2010. Caprion also serves as a biomarker center of excellence for the U.S. Government/NIH-NIAID for Biodefense research. For more information, please visit www.caprion.com.

For further information, please contact:  Patrick Tremblay

                                                           ptremblay@caprion.com

                                                           Tel: (514) 513-1998

Back to news list

© 2017 Caprion